PRINCETON, N.J., Sept. 13, 2011 /PRNewswire/ -- Kremers Urban Pharmaceuticals Inc. is pleased to announce that it has reached a settlement dismissing all pending litigation arising from its Abbreviated New Drug Application (ANDA) to market an extended release methylphenidate hydrochloride product, for which Concerta® is the reference listed drug product. The ANDA is currently under review with FDA.
The settlement includes a patent license and covenant, under existing ALZA Corporation patents under which Kremers Urban may commercially launch its methylphenidate ANDA product on July 1, 2012, or earlier under certain circumstances, pending FDA approval.
About Kremers Urban
Kremers Urban is the generic subsidiary of UCB. It is a specialty generic pharmaceutical company focused on difficult, “high barrier” to entry generic products. To learn more visit www.kremersurban.com.
For More Information Contact:
Antje Witte, Investor Relations
+49 2173 48 1866
antje.witte@ucb.com
SOURCE Kremers Urban Pharmaceuticals Inc.
